HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. The company employs 1,780 full-time employees The company went IPO on 2006-05-19. The firm operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.
Follow-Up Questions
Qui est le CEO de HUTCHMED (China) Ltd ?
Dr. Weiguo Su est le Chief Executive Officer de HUTCHMED (China) Ltd, il a rejoint l'entreprise depuis 2017.
Quelle est la performance du prix de l'action HCM ?
Le prix actuel de HCM est de $17.13, il a decreased de 1.83% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de HUTCHMED (China) Ltd ?
HUTCHMED (China) Ltd appartient à l'industrie Pharmaceuticals et le secteur est Health Care
Quelle est la capitalisation boursière de HUTCHMED (China) Ltd ?
La capitalisation boursière actuelle de HUTCHMED (China) Ltd est de $2.9B
Est-ce que HUTCHMED (China) Ltd est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 16 analystes ont établi des notations d'analystes pour HUTCHMED (China) Ltd, y compris 9 achat fort, 15 achat, 3 maintien, 0 vente et 9 vente forte
